<DOC>
	<DOCNO>NCT02103569</DOCNO>
	<brief_summary>The purpose study assess effect DCV/ASV/BMS-791325 fix dose combination ( FDC ) + 75mg BMS-791325 Pharmacokinetics ( PK ) oral contraceptive agent .</brief_summary>
	<brief_title>Drug Interaction Study OCP ( Norethindrone ( ND ) Acetate Ethinyl Estradiol ( EE ) ) With Combination Daclatasvir ( DCV ) Asunaprevir ( ASV ) BMS-791325</brief_title>
	<detailed_description>IND Number : 79,599 101,943 Other : Phase 1 Clinical Pharmacology drug interaction study healthy female subject</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone acetate , ethinyl estradiol , ferrous fumarate drug combination</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Norinyl</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Healthy female within age 1840 year Must Women Childbearing potential Must stable regimen oral contraceptive therapy least 3 consecutive month prior study start Subjects must significant acute chronic medical illness condition preclude safe use oral contraceptive Prior exposure DCV , ASV BMS791325 within 30 day dose study day 1 Smoking within 6 month study start</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>